Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corp reported an initial insider ownership filing for its Chief Financial Officer, Michael Messinger. The report shows he beneficially owns 3,000 shares of common stock, held directly, as of 11/14/2025. This documents the equity stake of a key executive and does not describe any specific stock transactions.
SeaStar Medical Holding Corporation is registering the offer and sale of up to $1,901,000 of its common stock under an at-the-market program with H.C. Wainwright & Co. acting as sales agent. The company previously established an ATM facility with an aggregate offering price of $2,279,989, of which $1,170,258 of common stock had been sold as of November 6, 2025. This supplement amends the prior prospectus to align the maximum amount that may be sold with the limits of General Instruction I.B.6 of Form S-3, which currently permits offerings up to an aggregate price of $1,901,390. SeaStar’s public float held by non-affiliates is stated as $44,394,521, based on 35,802,033 shares at $1.24 per share, and the company notes it has sold $12,896,813 of common stock under these I.B.6 limits over the prior 12-month period.
SeaStar Medical Holding Corporation reported that its Board of Directors appointed Michael Messinger, age 51, as Chief Financial Officer, effective November 14, 2025. He brings more than two decades of finance and accounting experience in drug discovery and development, including serving as CFO of ContraFect Corporation from October 2018 to November 2023 and holding senior roles at Lexicon Pharmaceuticals and Coelacanth Corporation.
The company has engaged Mr. Messinger under a consulting agreement dated October 31, 2025, under which he will receive a monthly fee of $15,000, and the company may terminate the agreement at any time with 30 days’ notice. SeaStar also filed the consulting agreement and a press release announcing his appointment as exhibits.
SeaStar Medical Holding Corporation (ICU) called a special stockholder meeting for December 18, 2025 at 10 am MST (virtual) to vote on capital structure changes. The Board seeks approval to effect a 1-for-10 reverse stock split of common stock at the Board’s discretion within one year, with fractional shares rounded up to the nearest whole share and no change to par value.
The Board also proposes reducing authorized common shares by 25,000,000 to 425,000,000, and an adjournment option if more time is needed to secure votes. The company cites Nasdaq’s $1.00 minimum bid requirement and potential delisting risk as key reasons to pursue the reverse split, noting the common stock closed at $0.5506 on November 3, 2025. Holders of record on November 3, 2025 may vote; 35,865,834 shares were outstanding as of that date. The Board recommends voting FOR all proposals.
SeaStar Medical Holding Corp. (ICU) reported Q3 2025 results showing early commercial traction and a strengthened balance sheet, alongside continued operating losses. Net revenue was $183 thousand for the quarter and $814 thousand for the first nine months, reflecting initial sales of QUELIMMUNE, the FDA-approved pediatric SCD therapy. Q3 net loss was $3.5 million, improving from $4.5 million a year ago, as operating expenses declined.
Cash rose to $13.8 million as of September 30, 2025, up from $1.8 million at year-end, driven by equity financings and warrant exercises. Stockholders’ equity improved to $11.5 million from a deficit at December 31, 2024, with 34.1 million shares outstanding at quarter-end and 36.0 million as of November 7, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting that additional capital is needed to fund operations and clinical programs. Subsequent to quarter-end, the company raised $1.2 million gross via its ATM and financed its D&O insurance with a short-term note.
SeaStar Medical Holding Corporation filed an 8-K stating it has furnished a press release with results for the three and nine months ended September 30, 2025, as Exhibit 99.1 under Item 2.02.
The information is furnished, not filed, under the Exchange Act, is not subject to Section 18 liabilities, and is not incorporated by reference. The company’s securities trade on Nasdaq as ICU (common) and ICUCW (warrants).
SeaStar Medical Holding Corporation called a virtual special meeting to seek stockholder approval for three items: a 1‑for‑10 reverse stock split, a reduction of authorized common shares by 25,000,000 to 425,000,000, and the ability to adjourn the meeting if needed. The meeting is set for December 18, 2025 at 10 am MST.
Under the reverse split, the Board may implement the action in its sole discretion within one year after the meeting; authorized share counts would not change under this item, and fractional shares would be rounded up to the nearest whole share. Proposal 2 would amend the charter to decrease authorized common shares to 425,000,000. The Board recommends voting FOR all proposals.
The company notes the reverse split is intended to help address Nasdaq’s minimum bid price requirement of
SeaStar Medical Holding Corporation launched an at‑the‑market offering of up to $2,279,989 of common stock under its S‑3 shelf, with H.C. Wainwright as sales agent. Sales may be made on Nasdaq or otherwise at prevailing prices. Wainwright will receive a 3.0% cash commission on gross sales, and will be deemed an underwriter for these transactions.
The company intends to use net proceeds for general corporate purposes. As of October 10, 2025, ICU last traded at $0.5716 and its listed warrants at $0.0301. SeaStar notes its public float was $42,019,639 (33,886,805 non‑affiliate shares at $1.24) and that it remains subject to Form S‑3 I.B.6 limits; it sold $11,726,556 over the prior 12 months. Nasdaq has notified the company of $1.00 minimum bid non‑compliance; SeaStar has until January 27, 2026 to regain compliance. If all ATM shares were sold at $0.5716, common stock outstanding would rise to up to 38,085,204 shares; the actual number depends on sale prices.
SeaStar Medical Holding Corporation reported that its Board of Directors approved increases to the annual base salaries of Chief Executive Officer Eric Schlorff, Chief Medical Officer Kevin Chung, and certain other members of management, effective October 1, 2025. Their salaries had been set at 2024 levels and then reduced by 20% in June 2025 as part of efforts to lower monthly operating expenses.
The Board also approved restoring each director’s cash retainer fees, and any additional cash retainer fees, back to original levels as of October 1, 2025, after these had likewise been reduced by 20% in June 2025. As a result of these compensation changes and other actions, the company expects monthly operating expenses to increase by approximately $50,000.
SeaStar Medical Holding Corporation reported that an independent Data Safety Monitoring Review Board recommended continuing its NEUTRALIZE-AKI pivotal trial of the Selective Cytopheretic Device in adults with acute kidney injury requiring continuous renal replacement therapy. The board cited zero device-related safety issues and advised increasing total trial enrollment to 339 patients to meet the original statistical powering assumptions.